CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and...

CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN and SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage Company focused on generating...

CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution World leader and trusted partner in rare diseases releases enhanced Whole Exome Sequencing (WES) solution to improve diagnosis in complex and unsolved patient casesNEW CentoXome® provides...

CENTOGENE Publishes Huge Dataset That Supports Genome Sequencing as a First-Line Diagnostic Test Publication demonstrates genome sequencing as the optimal standard for genetic testingStudy presents the largest cohort of its kind with over 1,000 index casesGenome sequencing minimizes stepwise...